|
|
Article: GENENTECH'S AVASTIN RIGHTS OUTSIDE U.S. GO TO ROCHE.
- Article from:
- BIOWORLD Today
- Article date:
- July 9, 2003
- Author:
CopyrightCOPYRIGHT 2003 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Brady Huggett , Associate Managing Editor
F. Hoffmann-La Roche Ltd., doing what just about everyone expected it to do, picked up its option on non-U.S. rights to Genentech Inc.'s cancer drug Avastin.
The positive Avastin data released in May that demonstrated the drug "far exceeded" what it was designed to show in a Phase III metastatic colorectal cancer trial were seen as a watershed event for anti- angiogenesis products and sent South San Francisco-based Genentech's stock up 44.7 percent the day they were made public. There has been plenty of buzz around Avastin since then, including a spirited American Society of Clinical Oncology meeting ...